Community-acquired pneumonia in the central desert and north-western tropics of Australia.

BACKGROUND: Community-acquired pneumonia (CAP) results in significant morbidity in central and north-western Australia. However, the nature, management and outcome of CAP are poorly documented. The aim of the study was to describe CAP in the Kimberley and Central Desert regions of Australia. METHODS: Prospective and retrospective cohort studies of inpatient management of adults with CAP at Alice Springs Hospital and six Kimberley hospitals were carried out. We documented demographic data, comorbidities, investigations, causes, CAP severity, outcome and concordance between prescribed and protocol-recommended antibiotics. RESULTS: Two hundred and ninety-three subjects were included. Aboriginal Australians were overrepresented (relative risk 8.1). Patients were notably younger (median age 44.5 years) and disease severity lower than in urban Australian settings. Two patients died within 30 days of admission compared with expected mortality based on Pneumonia Severity Index predictions of seven deaths (chi(2), P= 0.09). Disease severity and outcome did not differ between regions. Management differences were identified, including significantly more investigations, higher rates of critical care and broader antibiotic cover in Central Australia compared with the Kimberley. Sputum culture results showed Gram-negative organisms in both regions. However, Streptococcus pneumoniae was the most frequent organism isolated in the Kimberley and Haemophilus influenzae in Central Australia. CONCLUSION: CAP in this setting is an Aboriginal health issue. The low mortality observed and results of microbiology investigations support the use of existing antibiotic protocols. Larger studies investigating CAP aetiology are warranted. Addressing social and environmental disadvantage remains the key factors in dealing with the burden of CAP in this setting.

The involvement of New Zealand dentists in smoking cessation interventions.

OBJECTIVES: To determine the attitudes and practices of dentists towards smoking cessation interventions (SCI), to identify perceived barriers to providing SCI, and to determine the level of interest in future training in smoking cessation for dental staff. DESIGN: Self-administered questionnaire. SUBJECTS AND METHODS: 204 NZDA members in Wellington, Otago, and Southland completed a self-administered questionnaire about SCI. RESULTS: There has been little change in attitudes and practices of dentists towards SCI over the last decade. Few are actively involved in providing these services for their patients. Most dentists believe that there are significant barriers to providing SCI in their daily practice. CONCLUSION: Dentists require greater access to appropriate forms of training in SCI, and increased support (including resources) in order to increase the level of SCI provided in the dental setting.

Pharmacotherapy and osteoarthritis.

Therapy for osteoarthritis (OA) is aimed at relieving symptoms and at maximizing function. Therapies can be considered as either symptom modifying OA drugs (SMOADs) or as disease modifying OA drugs (DMOADs). Currently available agents fall into the category of SMOADs. Analgesic medications, particularly paracetamol and capsaicin, have proven efficacy in OA and are recommended first line therapies. Non-steroidal anti-inflammatory drugs (NSAIDs) do appear to provide extra symptomatic benefit for some patients but have greater toxicity. Newer generation NSAIDs may have safety advantages which remain to be confirmed in practice. Further therapies are being developed which aim to prevent cartilage damage and/or aid cartilage restoration, but these DMOADs remain in the experimental stage.